Press Release

IntrinsiQ CEO Examines Oncology Myths at 2010 ICORE Summit

Clinical Cancer Treatment Data Reveals Oncology Realities and Misperceptions

WALTHAM, Mass. (Sep 09, 2010) IntrinsiQ CEO Jeff Forringer will examine and debunk widely accepted misperceptions about oncology care, physician treatment decisions, and the cost of care at the ICORE/Magellan Oncology Summit in New York this week.

The oncology specialty is facing pressure like never before: Costs can be prohibitive, oral chemotherapy delivers patient convenience but increases compliance uncertainty, and physicians are tackling the need to standardize treatment practices across cancer care.  

Forringer will share insights into the realities of today’s clinical cancer care practices. He will draw from IntrinsiQ’s gold-standard data resources on longitudinal oncology treatment decisions nationwide to reveal how doctors truly practice medicine, the factors that bear the greatest influence on outcomes and costs, and continually changing perceptions of treatment efficacy.

WHAT:     Myth Busting: Who You Gonna Call?
                Myth vs. Reality in Oncology Management

WHO:       Jeff Forringer, CEO of IntrinsiQ, LLC

WHEN:      Friday, September 10, 2010 at 2:15 p.m.

WHERE:   7th Annual ICORE/Magellan Oncology Summit
               New York Marriott Marquis, 1535 Broadway, New York

###

About Magellan/ICORE
ICORE Healthcare, LLC, is redefining how America’s health plans manage complex specialty pharmaceuticals to ensure clinical excellence, while minimizing the costs in one of the fastest-growing areas of health care spending. ICORE is part of Magellan Health Services, Inc. (NASDAQ: MGLN), a leading specialty health care management organization whose customers include health plans, employers and government agencies nationwide.

About IntrinsiQ
IntrinsiQ, LLC is the leading provider of medical oncology clinical information systems and the premier source of US oncology data and analysis.  Each month, IntrinsiQ’s clinical software application, IntelliDose, captures the treatment decisions and details from more than 750 oncologists, for nearly 20,000 patients, creating a database unrivaled in accuracy, detail and timeliness of information about the medical oncology care process.  IntelliDose ensures patient safety though automation and standards designed to meet the needs of a specific practice, saving staff time, maximizing reimbursement and reducing operating costs. For more information, visit www.intrinsiq.com.

IntrinsiQ Company Contact:
781-647-1144
info@intrinsiq.com

IntrinsiQ Media Contact:
Rachel Round
(617) 969-919
intrinsiq@corporateink.com